Evidence suggests that the pericentric inversion of chromosome 9 (inv(9)) does not affect the aneuploidy rate (38.5%) after IVF. Herein, we report a successful live female twin birth through IVF/ICSI with a high aneuploidy rate from a couple within which the infertile father has inv(9)(p12q13). A couple (a 34-year-old male and a 35-year-old female) was referred to our clinic due to infertility. The wife has a child with her previous husband. Results from the infertility workup of both parents were normal. Karyotyping revealed that the inv(9)(p12q13) of the father was the only cytogenetic abnormality. Preimplantation genetic testing for aneuploidies (PGT-A) after IVF/ICSI revealed a high aneuploidy rate (77%; 10/13). Two euploid blastocysts were transferred, resulting in a successful live female twin birth. The presented case highlights the possibility that inv(9)(p12q13) in males may impact the fertility and euploidy rate. PGT-A facilitates the selection of qualified blastocysts for the optimization of live-birth outcomes.

Background/Objectives: The detection of ovarian cancer remains challenging due to the lack of reliable serum biomarkers that reflect malignant transformation rather than mere tumor presence. We developed a novel biotest using an immortalized human fallopian tube epithelial cell line (TY), which exhibits anchorage-independent growth (AIG) in response to cancer-associated serum factors. Methods: Sera from ovarian and breast cancer patients, non-cancer controls, and ID8 ovarian cancer-bearing mice were tested for AIG-promoting activity in TY cells. Results: TY cells (passage 96) effectively distinguished cancer sera from controls (68.50 ± 2.12 vs. 17.50 ± 3.54 colonies, p < 0.01) and correlated with serum CA125 levels (r = 0.73, p = 0.03) in ovarian cancer patients. Receiver operating characteristic (ROC) analysis showed high diagnostic accuracy (AUC = 0.85, cutoff: 23.75 colonies). The AIG-promoting activity was mediated by HGF/c-MET and IGF/IGF-1R signaling, as inhibition of these pathways reduced phosphorylation and AIG. In an ID8 mouse ovarian cancer model, TY-AIG colonies strongly correlated with tumor burden (r = 0.95, p < 0.01). Conclusions: Our findings demonstrate that the TY cell-based AIG assay is a sensitive and specific biotest for detecting ovarian cancer and potentially other malignancies, leveraging the fundamental hallmark of malignant transformation.

Background/Objectives: Occult endometrial carcinoma, incidentally diagnosed after hysterectomy for presumed benign disease, raises concerns regarding its incidence, the prognostic effects of minimally invasive surgery and morcellation, and subsequent management. This systematic review synthesized the available evidence and performed meta-analysis where appropriate. Methods: PubMed, Scopus, and the Cochrane Central Register were searched using a sensitivity-tested strategy. After de-duplication and screening, 76 studies met the eligibility criteria. Incidence was pooled using a random-effects meta-analysis of proportions with the Freeman–Tukey double-arcsine transformation. Subgroup analyses examined surgical contexts, including hysterectomy for benign disease, morcellation-specific cohorts, and pelvic organ prolapse surgery. Survival and management outcomes were synthesized narratively. Results: Among 68 studies with extractable denominators, the pooled incidence (proportion of hysterectomies with carcinoma on final pathology) of occult endometrial carcinoma following hysterectomy for benign disease was 0.33% (95% prediction interval, 0.04–0.87%). Incidence was lowest in selected morcellation cohorts (0.22%) and higher in unselected benign hysterectomy cohorts (0.33%) and prolapse populations (0.43%; test for subgroup differences, p = 0.03), with substantially higher rates among older patients. The pooled incidence of occult uterine malignancies, including sarcoma, was 0.54%. For endometrial carcinoma specifically, the limited observational evidence did not demonstrate a statistically significant association between power morcellation or laparoscopic surgery and poorer survival, although confidence intervals were wide. However, morcellation was associated with increased mortality among patients with uterine sarcoma. Occult endometrial carcinomas were predominantly early-stage and low-grade, with 81.8% classified as International Federation of Gynecology and Obstetrics IA, and approximately 91% achieving 5-year overall survival. In a small series of selected high-risk patients, completion staging resulted in upstaging in 25% and informed adjuvant treatment decisions. Limited observational data did not demonstrate a statistically significant survival benefit of complementary lymphadenectomy, although estimates were imprecise. Conclusions: Occult endometrial carcinoma occurs in approximately 0.2–0.4% of hysterectomies performed for benign disease, with a pooled incidence of 0.33% and higher rates among older patients. The limited observational evidence did not demonstrate a statistically significant association between minimally invasive surgery or morcellation and poorer survival, but estimates were imprecise; wide confidence intervals and potential residual confounding preclude conclusions regarding oncologic safety. Overall prognosis was favorable. These findings support age-informed preoperative counseling and appropriate endometrial evaluation, with individualized consideration of re-staging when occult carcinoma is identified.

Background/Objectives: To compare the prognostic value of the modeled cancer antigen-125 (CA-125) elimination rate constant K (KELIM) with that of conventional CA-125 kinetics (e.g., half-life) in epithelial ovarian cancer. Methods: PubMed, EMBASE, and Cochrane CENTRAL were searched from inception to 8 July 2026, using terms for ovarian cancer, CA-125 kinetics (KELIM, half-life, nadir), platinum-based chemotherapy, and survival or cytoreduction. Hazard ratios (HRs) and odds ratios (ORs) were pooled using random-effects models. Results: Thirty-seven studies were included (KELIM, 29; conventional, 8). Favorable KELIM was associated with longer overall survival (HR: 0.54, 95% confidence interval [CI]: 0.47–0.63; 14 cohorts; I² = 72%; moderate certainty) and progression-free survival (HR: 0.57, 95% CI: 0.51–0.63; 18 cohorts; I² = 62%) and with complete cytoreduction (OR: 3.34, 95% CI: 2.00–5.55; nine cohorts). Short CA-125 half-life was associated with longer overall survival (HR: 0.48, 95% CI: 0.38–0.60; three cohorts; low certainty); no study assessed both markers in the same cohort. Sensitivity analyses changed the estimates little. Conclusions: KELIM is a consistent prognostic factor in ovarian cancer. Its similarity to CA-125 half-life rests on an indirect comparison with older cohorts and does not establish equivalence or superiority. Evidence that KELIM predicts treatment benefit remains exploratory.